Sep. 8 at 2:02 PM
$NAMS lipfendra is simply the Repatha oral. We know what that does. M’eh. It does not lower Lp(a) and does not raise HDL where as Obi shows dramatic reduction in Lp(a) and significant improvement in HDL. Obi actually modifies how cholesterol shifts between particles, blocking the transfer of cholesterol from HDL to LDL. While its ~25% ApoB reduction is lower than Lipfendra’s, obicetrapib has a massive advantage in two other areas: It drives unprecedented increases in HDL cholesterol.It lowers Lipoprotein(a) by roughly 36% to 45%, outperforming Lipfendra’s ~25% reduction on that specific, high-risk genetic marker. [1] (https://www.sciencedirect.com/science/article/pii/S1933287425003435), [2] (https://pmc.ncbi.nlm.nih.gov/articles/PMC11393031/), [3] (https://pubmed.ncbi.nlm.nih.gov/39893110/), [4] (https://www.hcplive.com/view/obicetrapib-achieves-robust-ldl-c-reductions-in-phase-3-ascvd-trials), [5] (https://pmc.ncbi.nlm.nih.gov/articles/PMC12528909/)
